AlzeCure receives positive indicative clinical data with ACD856 in development for Alzheimer’s disease

STOCKHOLM, SWEDEN/ACCESSWIRE/March 8, 2022/ AlzeCure Pharma (STO:ALZCUR)(FRA:AC6)

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company developing a broad pipeline of drug candidates for diseases affecting the central nervous system, with projects in Alzheimer’s disease and pain, announced today Today indicative new data from the ongoing clinical study MAD phase I study with ACD856 showing that the substance reaches the brain, target organ of the substance developed for the treatment of Alzheimer’s disease.

ACD856, which is the Company’s lead drug candidate in the NeuroRestore platform, is currently undergoing a Phase I MAD (Multiple Ascending Dose) clinical study. The purpose of the study is to assess the safety and tolerability after repeated administration of different doses of the substance, but also to study the concentration of the substance in the body. AlzeCure has now received key data showing that ACD856 reaches the brain at relevant concentrations, which supports the further development program of the drug candidate as an oral treatment, among others, for Alzheimer’s disease.

“With these positive data showing that NeuroRestore ACD856 effectively crosses the blood-brain barrier and reaches the brain at high and relevant concentrations, we can move on to the next step – a signal detection study whose goal is to study the early effect signals,” said Martin Jönsson, CEO of AlzeCure Pharma. This project has been fully developed by AlzeCure, from the molecule to the clinical studies, and shows the capacity, scale and capacity of the organization”, continues Martin Jönsson.

ACD856 and the other substances in the NeuroRestore platform stimulate several important signaling systems in the brain, which can lead to improved cognition. Preclinical studies have shown that AlzeCure drug candidates enhance communication between nerve cells and improve cognitive abilities, including learning and memory functions.

For more information please contact

Martin Jonsson, CEO
Tel: +46 707 86 94 43
[email protected]

About AlzeCure Pharma AB (publ)

AlzeCure® is a Swedish pharmaceutical company that develops innovative new drug therapies for the treatment of serious diseases and conditions affecting the central nervous system, such as Alzheimer’s disease and pain – indications for which currently available treatments are very limited. The company is listed on the Nasdaq First North Premier Growth Market and is developing multiple parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.

NeuroRestore consists of two symptomatic drug candidates whose unique mechanism of action enables multiple indications, including Alzheimer’s disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinsons. The Alzstatin platform focuses on the development of disease-modifying and preventive drug candidates for the early treatment of Alzheimer’s disease and includes two drug candidates. Painless is the company’s pain research platform and contains two projects: ACD440, which is a drug candidate in clinical development for the treatment of neuropathic pain, and TrkA-NAM, which targets pain intense in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through pre-clinical research and development to an early clinical phase, and continuously works on commercial development to find suitable licensing solutions with other pharmaceutical companies.

FNCA Sweden AB, +46(0)8 528 00 399 [email protected], is the company’s certified advisor. For more information visit www.alzecurepharma.se

About NeuroRestore

NeuroRestore is a platform of symptom-relieving drug candidates for disease states in which cognitive abilities are impaired, such as Alzheimer’s disease, sleep apnea, traumatic brain injury and Parkinson’s disease. NeuroRestore stimulates several important signaling pathways in the brain, which, among other things, leads to improved cognition. In preclinical studies with NeuroRestore, we were able to show that our drug candidates improve communication between nerve cells and improve cognitive abilities. NeuroRestore stimulates specific central nervous system signaling pathways called neurotrophins, the best known being NGF (Nerve Growth Factor) and BDNF (Brain Derived Neurotrophic Factor). NGF and BDNF levels are disrupted in several disease states and signaling is reduced. The impaired function impairs communication between synapses, i.e. the contact surfaces of nerve endings, as well as the possibility of nerve cell survival, giving rise to cognitive impairment. Neurotrophins play a crucial role for nerve cell function, and impaired BDNF function has a strong genetic link with impaired cognitive ability in several different diseases, such as Alzheimer’s disease, Parkinson’s disease, brain injury trauma and sleep disorders. There is also a link between BDNF signaling and depression, which has grown even stronger in recent years.

Image attachments

Martin Jönsson CEO of AlzeCure Pharma

Attachments

AlzeCure receives positive indicative clinical data with ACD856 in development for Alzheimer’s disease

THE SOURCE: AlzéCure Pharma

See the source version on accesswire.com:
https://www.accesswire.com/692015/AlzeCure-Receives-Positive-Indicative-Clinical-Data-with-ACD856-in-Development-for-Alzheimers-Disease

Comments are closed.